Sarah Gerver

Lead Epidemiologist & Joint Head AMR PROGRESS Section

UK Health Security Agency

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Sarah Gerver is the Lead Epidemiologist and Joint Head of the AMR PROGRESS Section at the UK Health Security Agency. Her research focuses on antimicrobial resistance, bloodstream infections, and antibiotic prescribing practices, with recent publications examining the incidence and risk factors associated with infections caused by Escherichia coli and Klebsiella species. She has also contributed to studying the impact of procalcitonin testing on antibiotic usage during the COVID-19 pandemic, and the cost-effectiveness of guiding antibiotic prescriptions in acute hospital settings.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Mahableshwar Albur

University of Bristol

UNITED KINGDOM

View details

Paul Dark

The University of Manchester

UNITED KINGDOM

View details

Robert West

Professor of Biostatistics

University of Leeds

UNITED KINGDOM

View details

Enitan Carrol

Professor of Paediatric Infection

University of Liverpool

UNITED KINGDOM

View details

Edward Webb

University of Leeds

UNITED KINGDOM

View details

David Partridge

University of Sheffield

UNITED KINGDOM

View details

Hannah Higgins

UK Health Security Agency

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sarah Gerver

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Incidence, case-fatality rates and risk factors of bloodstream infections caused by Escherichia coli, Klebsiella species and Pseudomonas aeruginosa, England, April 2017 to March 2022

The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020

A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19

The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19

Trends in urine sampling rates of general practice patients with suspected lower urinary tract infections in England, 2015-2022: a population-based study.

Developing a model for decision-making around antibiotic prescribing for patients with COVID-19 pneumonia in acute NHS hospitals during the first wave of the COVID-19 pandemic: Qualitative results from the Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients (PEACH Study)

Nitrofurantoin resistance as an indicator for multidrug resistance: an assessment of <i>Escherichia coli</i> urinary tract specimens in England, 2015-19.

COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance.

Increased rates of hospital-onset Staphylococcus aureus bacteraemia in National Health Service acute trusts in England between June 2020 and March 2021: a national surveillance review.

Appropriateness of acute-care antibiotic prescriptions for community-acquired infections and surgical antibiotic prophylaxis in England: analysis of 2016 national point prevalence survey data.

Collaborators (7)

Mahableshwar Albur

Paul Dark

Robert West

Enitan Carrol

Edward Webb

David Partridge

Hannah Higgins

Make your next move.